Diagnostic accuracy of modern imaging following neoadjuvant therapy for breast cancer: a comparative analysis of ultrasound versus [18F] FDG PET/MRI in breast response assessment - Takeaways - MDSpire

Diagnostic accuracy of modern imaging following neoadjuvant therapy for breast cancer: a comparative analysis of ultrasound versus [18F] FDG PET/MRI in breast response assessment

  • By

  • Rosa Di Micco

  • Selin Saracoglu

  • André Pfob

  • Carla Canevari

  • Francesca Gallivanone

  • Lidija Antunovic

  • Fabrizia Gelardi

  • Paola Scifo

  • Ilaria Neri

  • Claudio Losio

  • Elena Venturini

  • Giovanna Della Vecchia

  • Goffredo Ferrarese

  • Nicole Rotmensz

  • Veronica Zuber

  • Sara Baleri

  • Giovanni Cisternino

  • Silvia Paola Corona

  • Francesca Calabretto

  • Mario Rampa

  • Luca Licata

  • Giulia Viale

  • Stefania Zambelli

  • Isabella Sassi

  • Giampaolo Bianchini

  • Pietro Panizza

  • Arturo Chiti

  • Joerg Heil

  • Oreste Davide Gentilini

  • June 18, 2026

  • 0 min

Share

  • 1

    This study compares ultrasound and [18F]FDG PET/MRI for predicting pathological complete response in breast cancer after primary systemic therapy.

  • 2

    The analysis included 143 patients, with 54 from a prospective trial and 89 from a retrospective database.

  • 3

    [18F]FDG PET/MRI had a sensitivity of 62% and specificity of 67%, while ultrasound had a sensitivity of 59% and specificity of 62%.

  • 4

    No significant differences were found between [18F]FDG PET/MRI and ultrasound in sensitivity or specificity for detecting response to treatment.

  • 5

    Subgroup analysis indicated varying sensitivity levels for both imaging modalities across different tumor molecular subtypes.

Original Source(s)

Diagnostic accuracy of modern imaging following neoadjuvant therapy for breast cancer: a comparative analysis of ultrasound versus [18F] FDG PET/MRI in breast response assessment

  • by Rosa Di Micco, Selin Saracoglu, André Pfob, Carla Canevari, Francesca Gallivanone, Lidija Antunovic, Fabrizia Gelardi, Paola Scifo, Ilaria Neri, Claudio Losio, Elena Venturini, Giovanna Della Vecchia, Goffredo Ferrarese, Nicole Rotmensz, Veronica Zuber, Sara Baleri, Giovanni Cisternino, Silvia Paola Corona, Francesca Calabretto, Mario Rampa, Luca Licata, Giulia Viale, Stefania Zambelli, Isabella Sassi, Giampaolo Bianchini, Pietro Panizza, Arturo Chiti, Joerg Heil, Oreste Davide Gentilini

  • June 18, 2026

Related Content

Multiparametric MRI-based nomogram integrating clinicopathological factors for predicting HER2 expression status in breast cancer

Polygenic Risk Scores for Breast Cancer Among African American Women With High Risk

Tumor microenvironment conversion through intelligent nanomedicine: a paradigm shift in overcoming chemoresistance